Clinical Trial Update: Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1) [Phase 2]

View source ↗

Summary

A Phase 2 MATCH subprotocol evaluating crizotinib for cancers with MET genetic alterations; results have been posted for this study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Multiple Myeloma
• Solid Tumors

Drugs mentioned

• Xalkori (crizotinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-03-19